Motilal Oswal sees 28% upside in Glenmark Pharma, hails $700 mln cancer drug deal as ‘new era’ for innovation play
The recent $700 million agreement through Glenmark’s subsidiary highlights the company’s strong research capabilities and is expected to substantially...
Read Full Article →